NCT04857684View on ClinicalTrials.gov

SBRT + Atezolizumab + Bevacizumab in Resectable HCC

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 18, 2021

Primary Completion Date

April 29, 2026

Study Completion Date

April 29, 2027

Conditions
Hepatocellular CarcinomaResectable Hepatocellular Carcinoma
Interventions
DRUG

Atezolizumab

Intravenous Infusion

DRUG

Bevacizumab

Intravenous Infusion

RADIATION

Stereotactic Beam Radiation Therapy (SBRT)

External beam radiation

Trial Locations (1)

02114

Massachusetts General Hospital Cancer Center, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT04857684 - SBRT + Atezolizumab + Bevacizumab in Resectable HCC | Biotech Hunter | Biotech Hunter